Nilotinib (NIL) vs. NIL Plus Pegylated Interferon alpha2B (IFN) Induction and NIL or IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1+Chronic Myeloid Leukemia (CML) Patients (PTS) in Chronic Phase
Ernst T, Saussele S, Burchert A, Baerlocher GM, Bruemmendorf TH, La Rosee PG, Heim D, Krause S, Le Coutre P, Niederwieser D, Lange T, Haenel M, Stegelmann F, Manz K, Himsel D, Hehlmann R, Fabisch C, Pfirrmann M, Hochhaus A (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: KARGER
City/Town: BASEL
Pages Range: 104-104
Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Ulm
Germany (DE)
Universitätsklinikum Jena
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
ELN Foundation
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Universitätsspital Basel
Switzerland (CH)
Asklepios Klinik Weissenfels
Germany (DE)
Klinikum Chemnitz
Germany (DE)
Universitätsklinikum Aachen (UKA)
Germany (DE)
Universitätsklinikum Mannheim
Germany (DE)
Universität Leipzig
Germany (DE)
Inselspital, Universitätsspital Bern
Switzerland (CH)
Schwarzwald-Baar Klinikum
Germany (DE)
Philipps-Universität Marburg
Germany (DE)
Germany (DE)
Universitätsklinikum Jena
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
ELN Foundation
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Universitätsspital Basel
Switzerland (CH)
Asklepios Klinik Weissenfels
Germany (DE)
Klinikum Chemnitz
Germany (DE)
Universitätsklinikum Aachen (UKA)
Germany (DE)
Universitätsklinikum Mannheim
Germany (DE)
Universität Leipzig
Germany (DE)
Inselspital, Universitätsspital Bern
Switzerland (CH)
Schwarzwald-Baar Klinikum
Germany (DE)
Philipps-Universität Marburg
Germany (DE)
How to cite
APA:
Ernst, T., Saussele, S., Burchert, A., Baerlocher, G.M., Bruemmendorf, T.H., La Rosee, P.G.,... Hochhaus, A. (2020). Nilotinib (NIL) vs. NIL Plus Pegylated Interferon alpha2B (IFN) Induction and NIL or IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1+Chronic Myeloid Leukemia (CML) Patients (PTS) in Chronic Phase. In ONCOLOGY RESEARCH AND TREATMENT (pp. 104-104). BASEL: KARGER.
MLA:
Ernst, Thomas, et al. "Nilotinib (NIL) vs. NIL Plus Pegylated Interferon alpha2B (IFN) Induction and NIL or IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1+Chronic Myeloid Leukemia (CML) Patients (PTS) in Chronic Phase." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2020. 104-104.
BibTeX: Download